Barton P. Bandy is CEO & President at ReShape Lifesciences Inc. (RSLS). They have made 12 open-market trades across 1 company since 2021, most recently 2022-08-05.
CIK 0001773309
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 12 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RSLS | 773,098 | $3.0M |
Shares reported on the most recent Form 4, priced at the 2022-08-11 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RSLS | SELL | 2022-08-05 | 2022-08-11 | $0.47 | $5K | -15.1% | -12.8% | -59.1% |
| RSLS | SELL | 2022-07-01 | 2022-07-06 | $0.55 | $6K | +0.4% | -11.7% | -42.8% |
| RSLS | SELL | 2022-06-01 | 2022-06-06 | $0.95 | $11K | -25.1% | -36.0% | -57.1% |
| RSLS | SELL | 2022-05-05 | 2022-05-12 | $0.77 | $9K | +18.1% | +10.4% | -31.0% |
| RSLS | SELL | 2022-04-01 | 2022-04-08 | $1.13 | $13K | -10.9% | -41.2% | -50.1% |
| RSLS | SELL | 2022-02-28 | 2022-03-02 | $1.06 | $7K | -17.9% | +8.6% | -3.8% |
| RSLS | SELL | 2022-01-31 | 2022-02-02 | $1.22 | $10K | +5.2% | -9.6% | -28.9% |
| RSLS | SELL | 2022-01-04 | 2022-01-28 | $1.79 | $13K | +1.7% | -6.8% | -29.6% |
| RSLS | SELL | 2021-12-02 | 2021-12-09 | $1.83 | $25K | -1.0% | -25.5% | -51.2% |
| RSLS | SELL | 2021-11-02 | 2021-11-16 | $2.69 | $36K | -9.6% | -3.7% | -44.7% |
| RSLS | SELL | 2021-10-01 | 2021-10-12 | $2.77 | $35K | -0.7% | -10.4% | -46.4% |
| RSLS | SELL | 2021-09-10 | 2021-09-17 | $2.89 | $1.7M | -8.9% | +3.8% | -28.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.